66th ASH Annual Meeting: 902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Brighter Tomorrow

Symposia: Health Services and Quality Improvement: Lymphoid Malignancies Oral and Poster Abstracts
Oral

Research, Adult, Acute Myeloid Malignancies, Clinical trials, Clinical Practice (Health Services and Quality), Lymphomas, Elderly, Non-Hodgkin lymphoma, Clinical Research, Health outcomes research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Patient-reported outcomes, Diseases, Real-world evidence, Clinical procedures, Aggressive lymphoma, Biological therapies, Treatment Considerations, Lymphoid Malignancies, Adverse Events, Survivorship, Emerging technologies, Technology and Procedures, Study Population, Human, Imaging, Pathology

Room 6B (San Diego Convention Center)

Moderators:

Muhammad Saad Hamid, MD, University of Tennessee Health Science Center and Abi Vijenthira, MD, SM, Princess Margaret Cancer Centre

Disclosures:

No relevant conflicts of interest to declare.

4:00 PM

385

Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma – an Economic Evaluation of the Fitness Trial

Bryony Dawkins, MSc¹^*, Georgios Gkountouras²^*, David Meads, PhD¹^*, Charlotte Pawlyn, PhD³, Kara-Louise Royle⁴^*, Ethan R Senior⁵^*, Dax Everritt⁵^*, Jenny Bird⁶^*, Stella Bowcock^7,8^*, Mark Drayson⁹^*, Sharon Gillson, BSc⁵^*, Catherine Olivier¹⁰^*, Matthew W. Jenner¹¹^*, John R Jones^12,13,14^*, Martin F Kaiser, MD¹⁵, Bhuvan Kishore¹⁶^*, Neil Rabin¹⁷^*, Roger G Owen, MD, MRCP, FRCPath¹⁸^*, Ruth M de Tute, MSc, PhD, FRCPath¹⁸^*, Christopher Parrish, MBBChir, MRCP, FRCPath, MA, PhD^4,19, David A. Cairns, PhD¹⁰^*, Alan Chant²⁰^*, Graham Jackson, MD²¹^* and Gordon Cook, PhD, DSc^4,19^*

¹University of Leeds, Academic Unit of Health Economics, Leeds, United Kingdom
²Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom
³Institute of Cancer Research, Sutton, United Kingdom
⁴Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
⁵Leeds Institute of Clinical Trials Research, Cancer Research UK Clinical Trials Unit, Leeds, United Kingdom
⁶Department of Haematology, University Hospitals Bristol NHS Foundation Trust, Cambridge, GBR
⁷Queen Mary's Sidcup NHS Trust, Sidcup, GBR
⁸King’s College Hospital, London, United Kingdom
⁹University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom
¹⁰Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
¹¹University Hospital Southampton, Southampton, United Kingdom
¹²Kings College Hospital, London, United Kingdom
¹³Brighton and Sussex Medical School, Brighton, United Kingdom
¹⁴East Sussex NHS Trust, Eastbourne, United Kingdom
¹⁵The Institute of Cancer Research, London, ENG, United Kingdom
¹⁶Heartofengland NHS FT, Birmingham, GBR
¹⁷Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
¹⁸HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
¹⁹Leeds Teaching Hospitals NHS Trust, Leeds Cancer Centre, Leeds, United Kingdom
²⁰Patient and Public Contributor, NA, United Kingdom
²¹University of Newcastle, Department of Haematology, Newcastle, United Kingdom

4:15 PM

386

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged ≥ 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Dasom Lee, MD¹, Sushma Bharadwaj, MD², Masooma S Rana, MBBS³^*, Alexandria Jensen⁴^*, William Wang⁵^*, Nima Ghalehsari, MD², Bita Sahaf⁵^*, Jayasindhu Mallampet⁵^*, Sarah Elkordy⁵^*, Theresa Latchford⁵^*, Sally Arai, MD⁵, Laura Johnston, MD⁵, Hitomi Hosoya, MD, PhD², Robert Lowsky, MD⁵^*, Robert S. Negrin, MD⁵, Andrew R. Rezvani⁵^*, Judith Shizuru⁵^*, Everett H. Meyer, MD, PhD⁶, Parveen Shiraz⁵^*, Lekha Mikkilineni, MD, MA², Wen-Kai Weng, MD, PhD², Lauren S. Maeda¹^*, Melody Smith, MD, MS⁶, Surbhi Sidana, MD⁶, Lori Muffly, MD⁶, Matthew J. Frank⁵, David B. Miklos, MD, PhD² and Saurabh Dahiya, MD, FACP⁵^*

¹Department of Medicine, Division of Oncology, Stanford University, Stanford, CA
²Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA
³Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Santa Clara, CA
⁴Quantitative Sciences Unit, Stanford University, Stanford, CA
⁵Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA
⁶Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA

4:30 PM

387

Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma

Jonas Paludo, MD¹, Amylou C Dueck, PhD², Vishal Bhatnagar, MD³^*, Abbie Y Brown⁴^*, Elizabeth J Cathcart-Rake, MD⁵^*, Devin B Copley¹^*, Matthew Diamond, MD, PhD³^*, Louis J Faust, Ph.D.⁶^*, Mallorie Fiero, PhD³^*, Scott F Huntington^7,8, Molly M Jeffery, Ph.D.^9,10^*, Lee Jones¹¹^*, Brie N Noble, MS²^*, Brad Power¹²^*, Jessica D Ritchie, MPH, PMP¹³^*, Joseph S Ross, MD, MHS^13,14^*, Kathryn J Ruddy, MD⁵^*, Sarah E Schellhorn, MD^14,15^*, Michelle Tarver, MD, PhD³^*, Lisa M Torre, MS, CCRP¹⁶^*, William A. Wood, MD, MPH¹⁷, Cary P Gross, MD^14,15^*, Paul G Kluetz, MD³^* and Gita Thanarajasingam, MD¹

¹Division of Hematology, Mayo Clinic, Rochester, MN
²Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ
³US Food and Drug Administration, Silver Spring, MD
⁴Health Education and Content Services, Mayo Clinic, Rochester, MN
⁵Department of Oncology, Mayo Clinic, Rochester, MN
⁶Division of Health Care Delivery Research, Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN
⁷Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT
⁸Yale School of Medicine, New Haven, CT
⁹Division of Health Care Delivery Research, Mayo Clinic, Rochester, MN
¹⁰Department of Emergency Medicine, Mayo Clinic, Rochester, MN
¹¹Patient Advocate, Arlington, VA
¹²Patient Advocate, CancerHacker Lab, Boston, MA
¹³Yale-New Haven Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, CT
¹⁴Department of Internal Medicine, Yale School of Medicine, New Haven, CT
¹⁵Yale's Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT
¹⁶Yale Center for Clinical Investigation (YCCI), Yale School of Medicine, New Haven, CT
¹⁷Division of Hematology, University of North Carolina, Chapel Hill, NC

4:45 PM

388

Evaluating the Comprehensive Geriatric Assessment Model As an Assessment Tool to Predict Chemotoxicity in Elderly Patients with Lymphoma

Xinjie Jonathan Tang, MBBS¹, Joanne Shu Xian Lee²^*, Esther Hian Li Chan^1,3^*, Sanjay De Mel, BSc, FRCPath, MRCP⁴^*, Yen-Lin Chee^2,3^*, Wee-Joo Chng^3,4,5, Michelle Limei Poon^1,3^*, Shi Hui Clarice Choong^1,3^* and Melissa Gaik-Ming Ooi^1,3^*

¹Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore
²Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
³Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
⁴Department of Haematology-Oncology, National University Cancer Institute, Singapore, National University Health System, Singapore, Singapore
⁵Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore

5:00 PM

389

Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients

Lauren N Scott¹^*, William Wesson, MD, MPH^1,2, Pilar Thangwaritorn, BS³^*, Raeef L Rahman, BS¹, Forat Lutfi, MD⁴, Marc Hoffmann, MD⁵, Zahra Mahmoudjafari, PharmD⁶^*, Muhammad Umair Mushtaq^7,8, Al-Ola Abdallah, MD^8,9, Sunil Abhyankar, MD⁷, Joseph P. McGuirk, DO⁴, Muhammad Mahdi Nashatizadeh, MD⁵^* and Nausheen Ahmed, MD^6,8

¹School of Medicine, University of Kansas Medical Center, Kansas City, KS
²US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS
³University of Kansas, Lawrence, KS
⁴University of Kansas Medical Center, Westwood, KS
⁵University of Kansas Medical Center, Kansas City, KS
⁶Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
⁷Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
⁸US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS
⁹University of Kansas Cancer Center, Fairway, KS

5:15 PM

390

AI Predicts Early Relapse Post-Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma Patients in a Multi-Center Real-World Study

Michelle Wang, PharmD, PhD¹^*, Krishna V. Komanduri, MD¹, Debajyoti Datta, MD, PhD¹^*, Ayan Patel, MS¹^*, Barbee Whitaker, PhD²^*, Artur Belov, PhD²^*, Benjamin Rubin, PhD¹^*, Rohit Vashisht, PhD¹^*, Rosa Rodriguez-Monguio, PhD¹^*, Pelin Cinar, MD, MS^1,3^*, Steven Anderson, PhD²^* and Atul Butte, MD, PhD¹^*

¹University of California, San Francisco, San Francisco, CA
²Food and Drug Administration, Silver Spring, MD
³Gilead Sciences, Foster City, CA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

902.O2.6 902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Brighter Tomorrow - Improving Safety of Treatments